Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13280890 | 0.71 | ALDH1A1 (0.32) | ALDH1A1BCHEPOLBMAOAACHE | |
| SCHEMBL592447 | 0.63 | MAOA (0.54) | ALDH1A1BCHEPOLBMAOAACHE | |
| SCHEMBL4890519 | 0.62 | ALDH1A1 (0.32) | ALDH1A1BCHEPOLBMAOAACHE | |
| SCHEMBL1628355 | 0.60 | — | — | |
| SCHEMBL219146 | 0.59 | — | — | |
| SCHEMBL8442480 | 0.59 | ALDH1A1 (0.33) | ALDH1A1BCHEPOLBMAOAACHE | |
| SCHEMBL14249193 | 0.55 | — | — | |
| SCHEMBL12570784 | 0.55 | MAOA (0.41) | ALDH1A1BCHEPOLBMAOAACHE | |
| Benzoquinone SCHEMBL460082 | 0.54 | ALDH1A1 (1.00) | ALDH1A1BCHEPOLBMAOAACHE | |
| Benzoquinone SCHEMBL5308519 | 0.54 | ALDH1A1 (1.00) | ALDH1A1BCHEPOLBMAOAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023138612-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | WO | claimed |
| US-5541299-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-07-30 | — | — | US | claimed |
| CN-117105958-A | Method for preparing 5-HT3 receptor modulators | 科岭源生物科技(深圳)有限公司 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023138612-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-07-27 | — | — | WO | disclosed |
| WO-2022237890-A1 | AZEPINE-TYPE FUSED RING COMPOUND AND PHARMACEUTICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2022-11-17 | — | — | WO | disclosed |
| WO-2020216203-A1 | AZAZINOINDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都科岭源医药技术有限公司 | 2020-10-29 | — | — | WO | disclosed |
| CN-111825702-A | Aza indazole derivative and preparation method and application thereof | 成都科岭源医药技术有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-111132964-A | Glucocorticoid receptor modulators | 欧瑞克制药公司 | 2020-05-08 | — | — | CN | disclosed |
| US-9511086-B2 | Method for improving immune system function by administering agents that inhibit DNA-dependent protein kinase-directed apoptosis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20120039867-A1 | Immune System Function in Conditions Characterized by Elevated Double Strand Breaks | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2004041191-A2 | METHODS FOR THE TREATMENT, PREVENTION AND MANAGEMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004039325-A2 | TREATMENT OF PAIN WITH JNK INHIBITORS | CELGENE CORPORATION (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040067953-A1 | Combination therapy for treating, preventing or managing proliferative disorders and cancers | SIGNAL PHARMACEUTICALS, LLC | 2004-04-08 | — | — | US | disclosed |
| WO-2003102151-A2 | MODULATING CELL DIFFERENTIATION AND TREATING MYELOPROLIFERTIVE DISORDERS WITH JNK/MKK INHIBITORS | CELGENE CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003099221-A2 | METHODS FOR USING JNK INHIBITORS FOR TREATING OR PREVENTING DISEASE-RELATED WASTING | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| US-5578711-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-26 | — | — | US | disclosed |
| US-5541299-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-07-30 | — | — | US | disclosed |
| US-5502171-A | Process for the preparation of dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1996-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067953-A1 | Combination therapy for treating, preventing or managing proliferative disorders and cancers | MAP3K1, MAP3K2, MAP2K2 | ALDH1A1 1939/4885BCHE 3297/4885POLB 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.